SVB Leerink

SVB Leerink

SVB Leerink originated as the healthcare investment banking and research arm of Silicon Valley Bank, which was acquired by First Citizens Bank in March 2023 following a series of bank failures. The unit was renamed SVB Leerink, retaining its specialised focus on the healthcare and life sciences sectors. The firm maintains offices across the United States as well as in London and Zurich. SVB Leerink provides equity research, capital raising, and merger-and-acquisition advisory services primarily to biotechnology, pharmaceutical, and medical-device companies. Its asset management arm manages institutional capital through long-only and hedge-fund strategies concentrated on healthcare equities. The firm's research team is among the largest dedicated healthcare equity research franchises on Wall Street, covering hundreds of publicly traded companies. The firm employs dozens of research analysts covering sub-sectors including oncology, rare diseases, and medical technology. Its asset management division has grown through separate accounts and commingled funds, though exact AUM is not publicly disclosed. Recent activity includes expanded coverage of emerging biotechnology themes such as gene editing and RNA therapies. SVB Leerink's structural differentiator is its lineage: it was carved out of a failed bank and now operates as a standalone entity backed by First Citizens, giving it regulatory independence while retaining specialised healthcare expertise. This hybrid structure—a bank subsidiary that also manages assets—is unusual in healthcare finance.